GLP-1 receptor agonists have substantially changed treatment for obesity and type 2 diabetes by producing weight loss, but they are associated with potential excess skeletal muscle loss. In contrast, pharmacologic inhibitors of the myostatin–activin pathway have been shown to promote skeletal muscle gain and reduce fat mass. The cardiac effects of chronic inhibition of this pathway in humans were not established prior to this study. Given the importance of cardiac safety for agents that modify muscle biology, a randomized trial was conducted to evaluate cardiovascular structure and function during extended exposure to bimagrumab, a monoclonal antibody that blocks the myostatin–activin signaling axis.
This was a randomized, double-blind, placebo-controlled study performed at a single commercial site. The treatment period lasted 6 months with up to 6 months of follow-up. The enrolled population comprised 68 healthy community-living men and women aged 60 to 86 years. Eligibility criteria and screening procedures are summarized in the full text; the abstract reports the age range and that participants were considered healthy at baseline.
Participants were randomized to receive intravenous bimagrumab 10 mg/kg or placebo. Cardiac structure and function were assessed by cardiovascular magnetic resonance (CMR) to provide quantitative measures of left ventricular geometry and performance. The co-primary cardiac endpoints reported were change in left ventricular mass index (LVMI) and change in left ventricular ejection fraction (LVEF) over the 6-month treatment period. Whole-body composition was measured by dual energy X-ray absorptiometry (DXA) to quantify total lean body mass (LBM) and total body fat mass (FM). Additional procedures referenced in study figures included electrocardiogram and maximal cardiopulmonary exercise testing, but the abstract focuses on CMR and DXA outcomes.
After 6 months of treatment, the between-group difference in change in LVMI (least squares mean) was 1.6 g/m2 with a 90% confidence interval of −0.2 to 3.4 (P = .148). The between-group difference in LVEF change was 2.0% with a 90% confidence interval of −0.4 to 4.4 (P = .176). These differences were not considered clinically relevant. The study reports that chronic inhibition of the myostatin–activin pathway with bimagrumab did not alter cardiac structure or systolic function compared with placebo in this cohort of healthy older adults.
Concurrent with the cardiac assessments, body composition changed significantly with bimagrumab. Total lean body mass increased by a mean of 5.5% (standard deviation 3.6) in the bimagrumab group compared with placebo, and total body fat mass decreased by −14% (SD 8.9) compared with placebo. Both body composition changes reached statistical significance (P < .001 for LBM and FM) at 6 months. Figures in the full article show percentage change from baseline at months 3 and 6 for these measures.
The abstract highlights cardiac safety findings (no clinically relevant change in LVMI or LVEF). Study flow figures note enrollment and retention issues related to administrative factors and the intensity of assessments (for example, maximal cardiopulmonary exercise tests). The abstract does not enumerate adverse event rates, specific noncardiac safety signals, or detailed follow-up findings; those elements are presented in the full text of the article.
In this randomized, double-blind trial in healthy older adults, six months of treatment with bimagrumab produced meaningful increases in skeletal lean body mass and reductions in fat mass without producing clinically relevant changes in cardiac structure (LVMI) or systolic function (LVEF) as measured by CMR. These data support the cardiac safety of extended myostatin–activin pathway inhibition in this study population and suggest that bimagrumab could be considered as a muscle-sparing strategy in adults undergoing weight loss, for example when using GLP-1 receptor agonists that may otherwise promote muscle loss.
The abstract reports primary cardiac and body composition outcomes but does not provide granular data on adverse events, longer-term cardiac follow-up beyond the reported 6 months, or subgroup analyses by sex, baseline cardiac metrics, or comorbidities. The single-site design and enrollment of healthy older adults limit immediate generalizability to populations with existing cardiovascular disease or to younger individuals. For these reasons, full-text review is necessary to evaluate safety event rates, protocol-specified secondary endpoints, and longer-term implications. Details not reported in the abstract include the exact adverse event profile and any post-treatment follow-up cardiac data beyond the primary 6-month comparisons.
Overall, the randomized evidence presented indicates that six months of bimagrumab at 10 mg/kg did not adversely affect LVMI or LVEF in healthy adults aged 60–86, while producing robust favorable effects on body composition.